Company

Covidien


Covidien revises Mo-99 supply through September

Industry News | Friday, August 13 2010
Covidien has posted molybdenum-99 (Mo-99) supply updates through September, and information for the U.S., Europe, Middle East, Africa and Canada. The Canadian National Research Universal reactor is currently projected to return to service in mid-August, and the Dutch High Flux Reactor in early September, and the resulting Mo-99 supply from each is expected several days after the reactors are back online, said Covidien.
 

Covidien's Q3 income rises, despite radiopharma slip

Financial News | Friday, August 06 2010
Covidien has reported strong results for the third quarter of fiscal 2010, which ended June 30.
 

ev3 settles class action suits over Covidien takeover

Industry News | Sunday, July 11 2010
ev3, an endovascular device company, has reportedly reached an agreement with the plaintiffs to settle the claims asserted in the stockholder class action lawsuits related to Covidien's proposed acquisition of ev3.
 

SNM past president calls for more aggressive solutions to moly shortage

Top Stories | Wednesday, June 09 2010
Written by Mary Tierney
Some progress is being made to avert the widespread molybdenum-99 (Mo-99) shortage in the U.S., but it’s not enough in the short term and especially not in the long term, according to Robert Atcher, PhD, MBA, immediate past president of SNM and University of New Mexico/LANL professor of pharmacy, bioscience division at Los Alamos National Laboratory, White Rock, N.M. Atcher spoke to members of the press Monday at the 57th annual meeting of SNM.
 

Holy Moly! How the U.S. Weathered a Moly Crisis in a Moly Shortage

Features | Wednesday, May 26 2010
Written by Michael Bassett
Nuclear medicine practitioners just haven’t been able to catch a break. First, Canada’s National Research University Reactor at Chalk River in Ontario shuts down for repairs, followed by the High Flux Reactor in Petten, the Netherlands. Then just as the Maria Research Reactor in Poland began to produce medical isotopes in March, that supply was interrupted in April by an act of nature—the eruption of the Eyjafjallajökull volcano in Iceland that grounded air transatlantic and intra-European travel for a week.
 

Covidien projects severe technetium shortage in May

Top Stories | Thursday, May 06 2010
As the molybdenum-99 (Mo-99) shortage continues, Covidien has updated its Mo-99 supply calendar and said that May remains challenging while the outlook is significantly improved in June.
 

Covidien posts net income jump for Q2, double-digit gains in radiopharma

Financial News | Friday, April 23 2010
Covidien has reported strong results for the second quarter of fiscal 2010, which ended March 27.
 

Feature: Volcanic ash further disrupts Mo-99 supply

Top Stories | Wednesday, April 21 2010
When the Maria Research Reactor in Poland began to produce medical isotopes in March, U.S. nuclear cardiology practices breathed a sigh of relief. Now, they are just holding their breath, hoping the huge cloud of grit and ash covering much of Northern and Central Europe dissipates, allowing many airports to resume flights of the precious molybdenum-99 (Mo-99), which is the parent isotope of technetium-99m.
 

FDA and Health Canada approve use of Mo-99 from Polish reactor

Top Stories | Thursday, March 11 2010
The U.S. Food and Drug Administration (FDA) and Health Canada have approved the use of the Maria Research Reactor in Poland as a site to irradiate highly-enriched uranium targets for molybdenum-99 (Mo-99) production, according to Covidien.
 

Poland's reactor to supply Mo-99 to Covidien

Industry News | Wednesday, February 17 2010
Covidien and the Institute of Atomic Energy in Poland have agreed to augment the global supply of molybdenum-99 (Mo-99) by adding the Poland’s Maria Research Reactor to the company's supply chain.
 

GE appoints Denman as CMO

Executive Announcements | Friday, February 05 2010
William Denman, MD, has been appointed chief medical officer (CMO) at GE Healthcare.
 

Report: Contrast-enhanced CT for H1N1 influences market

Industry News | Monday, February 01 2010
CT is being utilized as an adjunctive tool in the evaluation of patients presenting with complicated H1N1 flu cases in hospitals, which can be positive for both the technology and medical imaging agent manufacturers, said life sciences market research group Kalorama Information.
 

B&W nets $9M for Mo-99 production using low-enriched uranium

Industry News | Friday, January 29 2010
Babcock & Wilcox Technical Services Group (B&W TSG) has been awarded $9 million from the National Nuclear Security Administration for the development of reactor technology for medical isotope production using low enriched uranium.
 

Covidien posts 6.7% profit in Q1

Financial News | Thursday, January 21 2010
Medical device and drug manufacturer Covidien reported a 6.7 percent increase in profits in the first quarter of 2010, which ended Dec. 25, 2009.
 

Reactor shutdowns force Covidien to cut generator production in March

Top Stories | Wednesday, January 20 2010
There will be no Covidien generator production from March 21-25 in the Americas and from March 20-23 in Europe, the Middle East and Africa due to lack of molybdenum-99 supply, as all five major medical isotope reactors in Europe, Canada and South Africa will be off-line during this period.
 

Covidien sheds all U.S. radiopharmacies to Triad Isotopes

Friday, December 18 2009
Covidien, a provider of healthcare products, announced Thursday a definitive agreement to sell its U.S. radiopharmacies to Triad Isotopes of Orlando, Fla. Financial terms of the transaction were not disclosed.
 

FDA: GE, Bayer, Covidien MR agents carry highest risk

Industry News | Thursday, November 19 2009
After years of research regarding gadolinium-based contrast agents used during MRI being linked to the skin disease nephrogenic systemic fibrosis (NSF), the FDA has found the greatest risk in GE Healthcare’s Omniscan, Bayer HealthCare's Magnevist and Covidien’s Optimark.
 

Covidien charges sink Q4 profit

Financial News | Thursday, November 19 2009
Global healthcare products company Covidien took charges in its fiscal 2009 fourth quarter, which ended Sept. 30, that saw profits slide 86 percent compared with the same period last year.
 

Covidien restructures, divests units

Top Stories | Friday, September 04 2009
Covidien has reported several internal changes that will affect its financial reporting, including the combination of its pharmaceutical products and imaging solutions segments into a single operating segment called pharmaceuticals.
 

Judge limits Mallinckrodt’s damages in patent infringement suit

Industry News | Friday, August 28 2009
A federal judge has cut the potential damages Covidien's Mallinckrodt subsidiary can receive in its patent infringement case over medical injectors against two U.S. divisions of Bracco—Lake Success, N.Y.-based E-Z-EM and Acist Medical Systems of Eden Prairie, Minn.
 
Web Exclusives

Feature: U.S. needs national strategy to curb imaging overutilization

Medical imaging overutilization--a growing concern in the U.S.--exposes patients to unnecessary radiation, while also adding to rising healthcare costs, according to a study published online Aug. 24 in Radiology. In an interview, William R. Hendee, PhD, lead author, reviewed various methods by which medical imaging could be curtailed.

Radiology: Prelim study shows CE breast CT outperforms CT, mammo

Dedicated contrast-enhanced (CE) breast CT delivered significantly improved conspicuity of malignant breast lesions, including ductal carcinoma in situ (DCIS), compared with unenhanced breast CT and mammography, according to a study published in the September issue of Radiology.

Radiology: Rad role may evolve as image-guided biopsies trend up

CT, ultrasound and MRI have helped shift biopsy techniques away from more invasive approaches toward image-guided percutaneous techniques, according to a study published in the September issue of Radiology. The trend toward less-invasive approaches translates into enhanced safety and efficiency and could lead to more interaction between patients and radiologists.

CMS Webinar: Incentive payments to offset EHR adoption, not reimburse

The Centers for Medicare & Medicaid Services’ (CMS) EHR incentive payments are not considered reimbursement for money expended on EHR technology, but are intended to offset the cost associated with adoption and ongoing meaningful use, according to CMS during an Aug. 12 webinar.

CMS webinar: Eligible professionals can expect EHR incentives in 2011

Funding incentives for EHR use is the main goal of the Centers for Medicare & Medicaid Services' (CMS) meaningful use initiative, and there are incentive programs for both hospitals and eligible professionals, according to Elizabeth Holland, health insurance specialist at the Department of Health and Human Services, who spoke during a CMS-sponsored webinar Aug. 8.

Webinar: Stage 1 of meaningful use is for quality reporting acclimation

Stage 1 requirements for meaningful use incentives aim to strike a balance between the overall goal of EHR use and widespread adoption, while avoiding added work, said Jonathan Teich, MD, PhD, chief medical informatics officer at Elsevier Health Services, during a HIMSS webinar titled “Meaningful Use: Safety and Quality of Care.”

PORTALS

Advanced Visualization

Molecular Imaging

Integration Tools & Interoperability

More Portal Topics